Shenzhen Optimum Biological Technology Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Aug 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 14, 2027The maintenance fee for Cyclic Compound Acting as PDE4 Inhibitor (US 10,532,986) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,532,986 | Cyclic Compound Acting as PDE4 Inhibitor In force · High confidence | In force | High confidence | |
| US 11,136,315 | CXCR2 Antagonist In force · High confidence | In force | High confidence | |
| US 11,459,323 | Monocyclic B-Lactam Compound for Treating Bacterial Infection In force · High confidence | In force | High confidence | |
| US 12,338,218 | Crystal Form of BENZIMIDAZOLE-2-ONE Compound, Solvate Thereof, Crystal Form of Solvate Thereof, and Preparation Method Thereof In force · High confidence | In force | High confidence | |
| US 12,310,948 | Application of Monocyclic ß-Lactam Compound in Pharmacy In force · Medium confidence | In force | Medium confidence | |
| US 12,491,180 | Application of Compound in Treating Pneumonia In force · Medium confidence | In force | Medium confidence | |
| US 12,679,845 | Crystal Form of Triazolopyridine-Substituted Indazole Compound and Preparation Method Therefor In force · High confidence | In force | High confidence | |
| US 12,577,235 | Crystalline Form of CXCR2 Antagonist and Application Thereof In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
Every application published under this name has become a patent.